Amount paid for license of in-process research and development

No definition available.

Name:	aeri_AmountPaidUponExecutionOfCollaborationAgreement
Namespace Prefix:	aeri_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Purchase Agreement, Milestone Payments Contingent Upon the Achievement of Certain Approvals

+ References

No definition available.

+ Details

Name:	aeri_AssetPurchaseAgreementMilestonePaymentsContingentUpontheAchievementofCertainApprovals
Namespace Prefix:	aeri_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contingent Payments Due Upon Achievement Of Certain Development And Regulatory Milestones

+ References

No definition available.

+ Details

Name:	aeri_ContingentPaymentsDueUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
Namespace Prefix:	aeri_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Debt Instrument, Amount Of Collaborative Agreement To Be Paid

+ References

No definition available.

+ Details

Name:	aeri_DebtInstrumentAmountOfCollaborativeAgreementToBePaid
Namespace Prefix:	aeri_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

[Line Items] for Organization, Consolidation and Presentation of Financial Statements [Table]

+ References

No definition available.

+ Details

Name:	aeri_OrganizationConsolidationandPresentationofFinancialStatementsLineItems
Namespace Prefix:	aeri_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_NumberOfOperatingSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=aeri_EnvisiaTherapeuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=aeri_DelayedDrawTermLoanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Company The Company (Details)			1 Months Ended	3 Months Ended	12 Months Ended
The Company The Company (Details)	Dec. 31, 2020 USD ($)	Aug. 01, 2018 USD ($)	Oct. 31, 2017 USD ($) shares	Dec. 31, 2018 USD ($)	Dec. 31, 2018 USD ($) Segment	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jul. 23, 2018 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of operating segments \| Segment					1
Research and development					$ 86,123,000	$ 72,078,000	$ 52,394,000
Envisia Therapeutics Inc.
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Research and development			$ 24,800,000
Upfront cash payment			$ 10,500,000
Stock issued during period (in shares) \| shares			263,146
Stock issued during period, value			$ 14,300,000
Milestone payments contingent upon the achievement of certain approvals			$ 45,000,000
Collaborative Arrangement
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Amount paid due to collaboration arrangement		$ 6,000,000		$ 3,000,000
Research and development					$ 9,600,000
Contingent payments due (up to)				$ 75,000,000
Scenario, Forecast \| Collaborative Arrangement
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Amount of to be paid due to collaborative agreement	$ 9,000,000
Revolving Credit Facility \| Delayed Draw Term Loan
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Maximum borrowing capacity								$ 100,000,000